Axsome Therapeutics, Inc.
Axsome Therapeutics is a fully integrated biopharmaceutical company that develops and commercializes medicines for people affected by central nervous system conditions. Its three FDA-approved U.S. products are AUVELITY for major depressive disorder in adults, SUNOSI for excessive daytime sleepiness associated with obstructive sleep apnea or narcolepsy, and SYMBRAVO for acute treatment of migraine with or without aura in adults. Axsome sells its products and licenses marketing rights for SUNOSI in Europe and certain countries in the Middle East and North Africa. The company also develops investigational treatments for neurological and psychiatric conditions, including AXS-05 for Alzheimer’s disease agitation and smoking cessation, solriamfetol for several conditions, AXS-12 for narcolepsy, AXS-14 for fibromyalgia, and AXS-17 for epilepsy. Axsome uses proprietary medicinal chemistry and formulation technologies in drug development. It is headquartered in New York, New York.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $AXSM in the last 30 days.
See all $AXSM insider activity →Mizuho kept its Outperform rating on Axsome Therapeutics but reduced its price target to $272 from $284, a 4.2% decrease. The new target suggests a 94.8% upside from the Nov 3 close of $139.61. Recent analyst price targets for the company range from $220 to $273.
Morgan Stanley kept its Equal-Weight rating on Axsome Therapeutics but raised its price target to $249 from $247, suggesting an 83.1% upside from the Nov 2 close of $136.01. Recent analyst price targets for the company range from $220 to $273.
UBS kept its Buy rating on Axsome Therapeutics but reduced its price target to $239 from $256, a 6.6% cut. The new target suggests a 75.7% upside from the Nov 2 close of $136.01. Recent analyst price targets for the company range from $220 to $273.
Over the past 7 days, AlphAI's AI scored 24 news stories mentioning AXSM (Axsome Therapeutics, Inc.). Coverage has skewed bullish: 15 bullish, 4 neutral, and 5 bearish.
Recent AXSM coverage spans financial news and earnings.
Target reduction suggests modest downside pressure.
PT increase without a rating change suggests slightly improved expectations, but the Equal-Weight stance limits near-term conviction.
The target cut likely pressures near-term sentiment, but the maintained Buy rating may limit downside versus a downgrade.
Analyst target cut suggests weaker outlook.
Analyst target cut and mixed earnings may weigh on the stock.
AlphAI scores every news story that mentions AXSM with an AI model for sentiment and relevance, and aggregates insider trades from Axsome Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Mizuho kept its Outperform rating on Axsome Therapeutics but reduced its price target to $272 from $284, a 4.2% decrease. The new target suggests a 94.8% upside from the Nov 3 close of $139.61. Recent analyst price targets for the company range from $220 to $273.
Morgan Stanley kept its Equal-Weight rating on Axsome Therapeutics but raised its price target to $249 from $247, suggesting an 83.1% upside from the Nov 2 close of $136.01. Recent analyst price targets for the company range from $220 to $273.
UBS kept its Buy rating on Axsome Therapeutics but reduced its price target to $239 from $256, a 6.6% cut. The new target suggests a 75.7% upside from the Nov 2 close of $136.01. Recent analyst price targets for the company range from $220 to $273.
RBC Capital maintained its Outperform rating for Axsome Therapeutics but reduced its price target from $295 to $273. This implies a 100.7% upside from the Nov 2 close of $136.01. Recent analyst price targets for the company range from $220 to $295.
Guggenheim reduced Axsome Therapeutics' (AXSM) price target to $250 from $275, maintaining a Buy rating. AXSM's Q3 sales reached $207.6M, up 53% YoY, with strong gross margins. The company reported $259.7M in total revenue, beating estimates, but posted an adjusted loss of $0.25 per share. Analysts remain bullish, with price targets ranging from $238 to $380.
Baird reaffirmed its Outperform rating for Axsome Therapeutics but reduced its price target from $246 to $220, a 10.6% decrease. The new target suggests a 61.8% upside from the Nov 2 closing price of $136.01.
B.Riley reiterated a Buy rating and $300 target on Axsome Therapeutics (AXSM) after its Q3 2026 results. Revenue was $259.7M, up 52% YoY, beating estimates. AUVELITY revenue reached $207.6M, up 53% YoY. B.Riley expects cash flow breakeven in Q4 2026. AXSM stock fell premarket despite strong results.
Axsome Therapeutics (NASDAQ:AXSM) reported Q3 2025 revenue of $259.7M, up 52% YoY, beating estimates. Shares rose 2.13% premarket. EPS loss was -$0.25, better than expected. Growth driven by AUVELITY and SUNOSI sales. R&D and SG&A expenses increased. Company announced new trials and regulatory targets.
Axsome Therapeutics, Inc. (AXSM) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Axsome Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update Total 3Q 2026 net product revenue of $259.7 million, representing 52% year-over-year growth AUVELITY ® 3Q 2026 net product sales of $207.6 million, representing 53% year-ove
Axsome Therapeutics reported Q2 2026 sales of $180M for Auvelity and $36M for Sunosi, with peak sales estimates of $8B and $300M-$500M respectively. The company is expanding its pipeline with trials in various disorders. Moderna's revenue trends are compared, showing volatility due to reliance on a few products.
